



Kinase 2016: Next Generation Inhibitors

7th SCI/RSC symposium on kinase inhibitor design

Monday 16 - Tuesday 17 May 2016

BioCity, Nottingham, UK

**Organised by SCI's Fine Chemicals Group and
RSC's Biological and Medicinal Chemistry Sector in
partnership with Sygnature Discovery**

Kinase 2016: Next Generation Inhibitors

7th SCI/RSC symposium on kinase inhibitors

Monday 16 - Tuesday 17 May 2016, BioCity, Nottingham, UK

Synopsis

Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly 30 approved medicines to date. The seventh SCI/RSC symposium on kinase inhibitor design will feature several highly pertinent themes including new approaches and technologies to modulate and measure kinase function as well as diverse medicinal chemistry case studies. The symposium will also draw on the lessons from history to provide insight into the future direction of the field.

Attendees

In addition to medicinal discovery scientists wishing to further their knowledge of kinases, the meeting will also be of great value to the wider drug discovery community. It will provide transferable lessons and insight into how new approaches and technologies are being applied in a successful and maturing field of research.

Call for poster abstracts

Abstracts for poster presentations are now invited. Those presenting may also elect to advertise their poster via oral presentation of a single slide 'flash' poster. Submission details are available from the website with a deadline for entries of **Friday 18 March 2016**.

Exhibition

For further information and prices please email conferences@soci.org.



Confirmed speakers include

- **Design strategies for the development of selective kinase inhibitors**
Stefan Knapp, Johann Wolfgang Goethe-University, Germany
- **Filgotinib: a selective JAK1 inhibitor**
Christel Menet, Galapagos, Belgium
- **Discovery of non-covalent BTK inhibitors for the treatment of rheumatoid arthritis and lupus**
James Crawford, Genentech, USA
- **Identification of highly potent and mono-selective RIP1 kinase inhibitors targeting a unique allosteric pocket**
Phil Harris, GlaxoSmithKline, USA
- **Kinase identification of proximal substrates (KIPS): a novel chemical genetics approach for kinase substrate identification**
Jon Roffey, Cancer Research Technology, UK
- **Kinase drug discovery: past, present, and future**
Mark Bunnage, Pfizer, USA

For further updates/registration please see www.soci.org/events.

For further details:

SCI Conference Department
14/15 Belgrave Square,
London, SW1X 8PS
T: +44 (0) 20 7598 1561
E: conferences@soci.org
W: www.soci.org

